Q-omics provides the consensus-scored GALNT18 profile across patient tissues and cancer cell-line models. GALNT18 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GALNT18 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, GALNT18 RNA expression shows 19,161 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where GALNT18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT18 survival associations across molecular data types. GALNT18 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT18 RNA expression–survival associations across cancer types. High GALNT18 expression shows unfavorable associations in UVM, UCEC, ACC and HNSC, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GALNT18 RNA expression.
This table summarizes GALNT18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GALNT18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT18 shows lower tumor expression in KICH, THCA, KIRP and LUAD and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher GALNT18 RNA expression in tumor versus normal tissue (log2 FC = +1.925, t-test p < 0.001).
This table shows molecular features associated with GALNT18 in patient tissues and cancer cell lines. In patient samples, GALNT18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
